Cargando…
Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
INTRODUCTION: Data comparing response to originator and biosimilar infliximab in anti-TNF-α naïve and non-naïve Crohn’s disease patients is limited. AIM: To assess the efficacy, safety, and tolerability of a biosimilar infliximab in comparison to the originator drug in anti-TNF-α naïve and non-naïve...
Autores principales: | Kaniewska, Magdalena, Rosolowski, Mariusz, Moniuszko, Andrzej, Rydzewska, Grazyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456772/ https://www.ncbi.nlm.nih.gov/pubmed/34584581 http://dx.doi.org/10.5114/pg.2020.100750 |
Ejemplares similares
-
The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017) -
Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022) -
Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022) -
The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
por: Lewandowski, Konrad, et al.
Publicado: (2021) -
The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome
por: Lewandowski, Konrad, et al.
Publicado: (2022)